Emerging antiarrhythmic agents: a personal view from the Far East

Area of Science:

• Cardiology
• Pharmacology

Background:

• Current arrhythmia treatments include electronic devices (pacemakers, defibrillators) and ablation techniques.
• Antiarrhythmic drugs represent a classical approach, but their effectiveness and safety remain under evaluation.

Purpose of the Study:

• To review recent advancements in understanding arrhythmias, cardiac ionic channels, and antiarrhythmic drugs.
• To discuss the development of novel antiarrhythmic drug candidates.

Main Methods:

• Literature review of papers published after 2000.
• Discussion of recent developments in cardiac electrophysiology and pharmacology.

Main Results:

• The market for antiarrhythmic drugs is currently small.
• Various multichannel-acting drugs are emerging as potential candidates.

Conclusions:

• Understanding cardiac ionic channels as protein targets is crucial for antiarrhythmic drug development.
• Accurate clinical effectiveness and safety data are essential for drug approval.
• Development is focused on atrium-selective drugs (e.g., IKur, IKACh, IKAde blockers) and amiodarone-like multichannel agents.